BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for MoonLake Immunotherapeutics:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-08 6:48 pm Sale | 2024-10-04 | 13D | MoonLake Immunotherapeutics MLTX | BIOTECHNOLOGY VALUE FUND L P | 19,751,284 31.400% | -2,000,000 (-9.19%) | Filing |
| 2024-03-05 4:59 pm Unchanged | 2024-02-29 | 13D | MoonLake Immunotherapeutics MLTX | BIOTECHNOLOGY VALUE FUND L P | 21,751,284 34.600% | 0 (Unchanged) | Filing |
| 2023-06-30 4:41 pm Unchanged | 2023-06-27 | 13D | MoonLake Immunotherapeutics MLTX | BIOTECHNOLOGY VALUE FUND L P | 21,751,284 35.800% | 0 (Unchanged) | Filing |
| 2022-04-18 4:49 pm Purchase | 2022-04-05 | 13D | MoonLake Immunotherapeutics MLTX | BIOTECHNOLOGY VALUE FUND L P | 21,751,284 58.900% | 21,751,284 (New Position) | Filing |